Literature DB >> 33443717

Update in carcinoid heart disease - the heart of the matter.

Kira Oleinikov1,2, Amit Korach2,3, David Planer2,4, Dan Gilon2,4, Simona Grozinsky-Glasberg5,6.   

Abstract

Carcinoid heart disease (CHD) is a paraneoplastic cardiac manifestation occurring in patients with carcinoid syndrome (CS) and advanced neuroendocrine malignancy. In about 20-40% of patients with CS, chronic exposure to tumor-released circulating vasoactive peptides typically results in right-sided valvular fibrosis leading to valve dysfunction and right heart failure. CHD remains a significant cause of morbidity and mortality. The management of patients with CHD is complex, as both the systemic malignant disease and the heart involvement have to be addressed. Early diagnosis and timely surgical intervention in selected patients are of utmost importance and offer a survival benefit. In patients with advanced carcinoid heart disease, valve replacement surgery is the most effective option to alleviate cardiac symptoms and contribute to survival outcomes. A collaboration of a multidisciplinary team in centers with experience is required to provide optimal patient management. Here, we review the current literature regarding CHD presentation, pathophysiology, diagnostic tools, and available treatment strategies.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature.

Entities:  

Keywords:  5-HT; 5-hydroxytryptamine; B-type natriuretic peptide; Carcinoid heart disease; Carcinoid syndrome; Echocardiography; Heart valve disease; NT-proBNP; Neuroendocrine tumor

Mesh:

Year:  2021        PMID: 33443717     DOI: 10.1007/s11154-020-09624-y

Source DB:  PubMed          Journal:  Rev Endocr Metab Disord        ISSN: 1389-9155            Impact factor:   9.306


  63 in total

1.  Carcinoid heart disease: relationship of circulating vasoactive substances to ultrasound-detectable cardiac abnormalities.

Authors:  L Lundin; I Norheim; J Landelius; K Oberg; E Theodorsson-Norheim
Journal:  Circulation       Date:  1988-02       Impact factor: 29.690

Review 2.  Diagnosing and Managing Carcinoid Heart Disease in Patients With Neuroendocrine Tumors: An Expert Statement.

Authors:  Joseph Davar; Heidi M Connolly; Martyn E Caplin; Marianne Pavel; Jerome Zacks; Sanjeev Bhattacharyya; Daniel J Cuthbertson; Rebecca Dobson; Simona Grozinsky-Glasberg; Richard P Steeds; Giles Dreyfus; Patricia A Pellikka; Christos Toumpanakis
Journal:  J Am Coll Cardiol       Date:  2017-03-14       Impact factor: 24.094

3.  An analysis of 8305 cases of carcinoid tumors.

Authors:  I M Modlin; A Sandor
Journal:  Cancer       Date:  1997-02-15       Impact factor: 6.860

4.  Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study.

Authors:  Daniel M Halperin; Chan Shen; Arvind Dasari; Ying Xu; Yiyi Chu; Shouhao Zhou; Ya-Chen Tina Shih; James C Yao
Journal:  Lancet Oncol       Date:  2017-02-24       Impact factor: 41.316

Review 5.  Serotonin pathway in carcinoid syndrome: Clinical, diagnostic, prognostic and therapeutic implications.

Authors:  Giuseppe Fanciulli; Rosaria M Ruggeri; Erika Grossrubatscher; Fabio Lo Calzo; Troy D Wood; Antongiulio Faggiano; Andrea Isidori; Annamaria Colao
Journal:  Rev Endocr Metab Disord       Date:  2020-12       Impact factor: 6.514

Review 6.  Clinical Syndromes Related to Gastrointestinal Neuroendocrine Neoplasms.

Authors:  Georgios Boutzios; Gregory Kaltsas
Journal:  Front Horm Res       Date:  2015-08-14       Impact factor: 2.606

7.  Early and Late Outcomes of Surgical Treatment in Carcinoid Heart Disease.

Authors:  Heidi M Connolly; Hartzell V Schaff; Martin D Abel; Joseph Rubin; J Wells Askew; Zhuo Li; Jacob J Inda; Sushil A Luis; Rick A Nishimura; Patricia A Pellikka
Journal:  J Am Coll Cardiol       Date:  2015-11-17       Impact factor: 24.094

8.  Factors associated with progression of carcinoid heart disease.

Authors:  Jacob E Møller; Heidi M Connolly; Joseph Rubin; James B Seward; Karen Modesto; Patricia A Pellikka
Journal:  N Engl J Med       Date:  2003-03-13       Impact factor: 91.245

9.  Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States.

Authors:  Arvind Dasari; Chan Shen; Daniel Halperin; Bo Zhao; Shouhao Zhou; Ying Xu; Tina Shih; James C Yao
Journal:  JAMA Oncol       Date:  2017-10-01       Impact factor: 31.777

10.  Serial surveillance of carcinoid heart disease: factors associated with echocardiographic progression and mortality.

Authors:  R Dobson; M I Burgess; J W Valle; D M Pritchard; J Vora; C Wong; C Chadwick; B Keevi; J Adaway; U Hofmann; G J Poston; D J Cuthbertson
Journal:  Br J Cancer       Date:  2014-09-11       Impact factor: 7.640

View more
  6 in total

1.  Arterial function, biomarkers, carcinoid syndrome and carcinoid heart disease in patients with small intestinal neuroendocrine tumours.

Authors:  Camilla Schalin-Jäntti; Niina Matikainen; Iiro Kostiainen; Noora Karppinen; Piia Simonen; Milla Rosengård-Bärlund; Riikka Lindén; Maija Tarkkanen; Daniel Gordin; Janne Rapola
Journal:  Endocrine       Date:  2022-05-10       Impact factor: 3.925

2.  Delayed Presentation of Carcinoid Heart Disease and Subsequent Modified Healthcare Delivery in the COVID-19 Era.

Authors:  Alexandra N Willauer; Richard Hajjar; Christina W Estes; Kelly R Laipply
Journal:  CASE (Phila)       Date:  2022-02-17

Review 3.  Cardiovascular Toxicities Secondary to Biotherapy and Molecular Targeted Therapies in Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials.

Authors:  Charalampos Aktypis; Maria-Eleni Spei; Maria Yavropoulou; Göran Wallin; Anna Koumarianou; Gregory Kaltsas; Eva Kassi; Kosmas Daskalakis
Journal:  Cancers (Basel)       Date:  2021-04-30       Impact factor: 6.639

Review 4.  Bronchial Carcinoids: From Molecular Background to Treatment Approach.

Authors:  Marta Araujo-Castro; Eider Pascual-Corrales; Javier Molina-Cerrillo; Nicolás Moreno Mata; Teresa Alonso-Gordoa
Journal:  Cancers (Basel)       Date:  2022-01-20       Impact factor: 6.639

5.  Multimodality imaging in the diagnostic approach to a patient with carcinoid heart disease involving four heart valves.

Authors:  Shirin Habibi Khorasani; Mozhgan Parsaee; Niloufar Samiei; Mahshid Hesami; Feridoun Noohi; Saeid Hosseini; Golnaz Houshmand
Journal:  Clin Case Rep       Date:  2022-07-25

6.  Ablation of typical atrial flutter as therapeutic component in carcinoid heart disease: a case report.

Authors:  Susann Groschke; Rolf Weinert; Björn Becker; Gert Richardt; Ralph Tölg; Leon Iden; Martin Borlich
Journal:  J Med Case Rep       Date:  2022-02-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.